Cellares said it is facing a major financial and operational blow after Bristol Myers Squibb terminated their manufacturing collaboration tied to Breyanzi (lisocabtagene maraleucel). The partnership was described as $380 million and ended based on manufacturing requirements for commercial-scale production. Cellares disputes BMS’s characterization that its Cell Shuttle system could not meet the necessary requirements. The company said it had already manufactured GMP drug product in an FDA-regulated clinical program with doses meeting release specifications and delivered on time. The termination is likely to trigger restructuring, and Cellares indicated it plans to resize its organization while reassessing the timing and structure of international expansion. The dispute highlights recurring supply-chain pressure in CAR-T manufacturing and how commercial expectations for process performance can quickly reshape external manufacturing partner strategies.